Ignite Creation Date:
2024-07-17 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06461624
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-17
First Post:
2024-06-05
Brief Title:
Clinical Trial of Autologous GPC3 CAR-T Cells CBG166 Therapy for Advanced Hepatocellular Carcinoma
Sponsor:
Zhejiang University
Organization:
Zhejiang University
Study Overview
Official Title:
Clinical Trial of Autologous GPC3 CAR-T Cells CBG166 Therapy for Advanced Hepatocellular Carcinoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A phase I clinical study of 4th generation chimeric antigen receptor T Cells targeting glypican-3 CAR-GPC3 T Cells in patients with advanced hepatocellular carcinoma
Detailed Description:
This is a single-arm dose-escalation open exploratory clinical study to evaluate the safety and tolerability preliminary efficacy and PKPD characteristics of GPC3 CAR-T cells in the treatment of advanced hepatocellular carcinoma
Primary objectives To evaluated the safety of GPC3 CAR-T cells in patients with advanced hepatocellular carcinoma
Secondary objectivesTo evaluate the preliminary efficacy and PKPD characteristics of CBG166
Primary objectives To evaluated the safety of GPC3 CAR-T cells in patients with advanced hepatocellular carcinoma
Secondary objectivesTo evaluate the preliminary efficacy and PKPD characteristics of CBG166
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None